AXSOME THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 73.76 USD | +0.09% |
|
+0.93% | -7.33% |
| 30/04 | North American Morning Briefing : More Earnings -2- | DJ |
| 29/04 | Axsome Therapeutics Phase 3 Alzheimer's Treatment Trial is High Risk, High Reward, Morgan Stanley Says | MT |
Chart calendar Axsome Therapeutics, Inc.
a636c0fad7e10617473a5e9290dd0f.XXwix4Nr5dGjOK_pgYRsXtnqHvcvDU77z1SxgZSQW9Y.ERkWlO0mjJ_0QZ6Y8-9YJ5DcXc9NTz63gRnB9N7qK5kvT0S0yibS6cBMnw~73de531b8ea0b9f565a35368ab1165e2
Upcoming events on Axsome Therapeutics, Inc.
Past events on Axsome Therapeutics, Inc.
| 17/04/2024 11:15 pm | American Academy of Neurology Meeting - Craig Chepke |
| 17/04/2024 07:30 pm | American Academy of Neurology Meeting - Yaroslav Winter |
| 17/04/2024 07:30 pm | American Academy of Neurology Meeting - David Gozal |
| 16/04/2024 11:15 pm | American Academy of Neurology Meeting - Stewert Tepper |
| 16/04/2024 08:45 pm | American Academy of Neurology Meeting - Anton P. Porsteinsson |
| 16/04/2024 07:30 pm | American Academy of Neurology Meeting - Peter McAllister |
| 25/03/2024 05:30 pm | AXS-12 Symphony Phase 3 Trial Results Call |
| 13/03/2024 06:50 pm | Leerink Partners Global Biopharma Conference - Fireside Chat |
| 06/03/2024 08:20 pm | TD Cowen Health Care Conference |
| 20/02/2024 06:30 pm | Q4 2023 Earnings Call |
| 20/02/2024 05:30 pm | Q4 2023 Earnings Release |
| 07/12/2023 06:30 pm | R&D Day |
| 03/12/2023 | American College of Neuropsychopharmacology Meeting |
| 28/11/2023 08:00 pm | Piper Sandler Healthcare Conference |
| 09/11/2023 12:55 am | Truist Securities Healthcare Conference |
| 07/11/2023 09:40 pm | Guggenheim Securities Inflammation & Immunology Conference |
| 06/11/2023 06:30 pm | Q3 2023 Earnings Call |
| 06/11/2023 05:30 pm | Q3 2023 Earnings Release |
| 29/09/2023 | Thrive Together Narcolepsy Network Conference |
| 20/09/2023 07:50 pm | TD Cowen Novel Mechanisms in Neuropsychiatry Summit |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 0,00 0,00 - | 50,0 47,0 6.48% | 271 268 0.91% | 376 |
|
EBITDA Million USD | Released Forecast Spread | 0,00 0,00 - | -99,1 -87,8 -12.83% | -125 -121 -2.99% | -175 -158 -11.24% | -225 -166 -35.15% | -151 |
|
EBIT Million USD | Released Forecast Spread | -67,2 -60,0 -12.07% | -99,1 -96,2 -3.01% | -125 -128 2.23% | -180 -161 -11.76% | -232 -184 -26.09% | -166 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -68,5 -61,2 -11.95% | -102 -99,7 -1.97% | -130 -134 2.99% | -187 -178 -5.12% | -238 -194 -23.13% | -178 |
|
Net income Million USD | Released Forecast Spread | -68,3 -60,8 -12.32% | -103 -100 -2.9% | -130 -135 3.34% | -187 -178 -5.06% | -239 -194 -23.53% | -185 |
|
EPS USD | Released Forecast Spread | -2,01 -1,77 -13.48% | -2,77 -2,67 -3.71% | -3,47 -3,58 3.03% | -4,60 -4,40 -4.6% | -5,27 -4,25 -23.9% | -3,88 |
| Announcement Date | 12/03/20 | 01/03/21 | 01/03/22 | 27/02/23 | 20/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 0,00 0,00 - | 0,00 0,00 - | 8,82 6,92 27.48% | 16,8 17,1 -1.24% | 24,4 21,7 12.06% | 94,6 26,3 259.35% | 46,7 40,9 14.05% | 57,8 54,9 5.35% | 71,5 69,0 3.61% | 72,9 | 87,7 | 101 | 118 | 110 |
|
EBITDA Million USD | Released Forecast Spread | -40,8 -36,6 -11.49% | -58,2 -43,5 -33.98% | -96,5 -55,1 -75.08% | -62,4 | -54,8 | -48,1 | -42,9 | |||||||
|
EBIT Million USD | Released Forecast Spread | -32,6 -35,6 8.29% | -38,3 -36,9 -3.63% | -39,2 -43,3 9.51% | -42,5 -40,3 -5.42% | -59,9 -43,4 -38.1% | -6,37 -51,0 87.51% | -65,1 -53,5 -21.59% | -62,1 -55,0 -12.87% | -98,3 -52,6 -86.91% | -55,6 | -46,0 | -36,5 | -24,0 | -28,0 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -34,0 -36,6 7.05% | -39,6 -38,2 -3.68% | -41,4 -45,1 8.06% | -44,8 -45,3 1.01% | -61,2 -46,8 -30.85% | -8,64 -30,8 71.98% | -67,8 -54,1 -25.28% | -62,9 -57,6 -9.11% | -99,0 -54,1 -82.89% | -57,3 | -46,9 | -37,1 | -22,3 | -24,7 |
|
Net income Million USD | Released Forecast Spread | -34,0 -37,2 8.77% | -39,6 -37,8 -4.82% | -41,4 -44,5 6.92% | -44,8 -45,0 0.35% | -61,2 -48,4 -26.45% | -11,2 -38,3 70.71% | -67,2 -55,3 -21.49% | -62,2 -57,0 -9.06% | -98,7 -54,0 -82.55% | -58,5 | -48,3 | -38,9 | -27,9 | -24,7 |
|
EPS USD | Released Forecast Spread | -0,90 -1,00 9.59% | -1,03 -1,00 -2.72% | -1,06 -1,24 14.4% | -1,07 -1,09 1.63% | -1,41 -1,14 -23.83% | -0,26 -0,88 70.54% | -1,54 -1,24 -24.6% | -1,32 -1,23 -7.23% | -2,08 -1,16 -78.56% | -1,23 | -1,03 | -0,82 | -0,58 | -0,66 |
| Announcement Date | 01/03/22 | 02/05/22 | 09/08/22 | 07/11/22 | 27/02/23 | 09/05/23 | 07/08/23 | 06/11/23 | 20/02/24 | - | - | - | - | - |
| 02/05/2024 | BRIDGEBIO PHARMA, INC.: Q1 2024 Earnings Release (Projected) |
| 02/05/2024 | TWIST BIOSCIENCE CORPORATION: Q2 2024 Earnings Release |
| 02/05/2024 | SK BIOSCIENCE CO.,LTD.: Q1 2024 Earnings Release |
| 06/05/2024 04:30 pm | AXSOME THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 07/05/2024 | BIOTEST AG: Q1 2024 Earnings Release |
| 07/05/2024 | AVIDITY BIOSCIENCES, INC.: Q1 2024 Earnings Release (Projected) |
| 07/05/2024 | REVANCE THERAPEUTICS, INC.: Q1 2024 Earnings Release (Projected) |
| 07/05/2024 | APELLIS PHARMACEUTICALS, INC.: Q1 2024 Earnings Release |
| 07/05/2024 11:30 am | BIOGAIA AB: Q1 2024 Earnings Release |
| 08/05/2024 | ADMA BIOLOGICS, INC.: Q1 2024 Earnings Release (Projected) |
Past sector events for Axsome Therapeutics, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- AXSM Stock
- Calendar Axsome Therapeutics, Inc.
